Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.41 |
| ▸ | LATS1 | O95835 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31356303 | 0.86 | LATS1 (0.56) | ABCG2EGFRLATS1CSNK2A1AURKA | |
| SCHEMBL31356308 | 0.84 | EPHB4 (0.45) | ABCG2LATS1CSNK2A1CDK5DYRK1A | |
| SCHEMBL31485515 | 0.84 | CSNK2A1 (0.49) | EGFRCSNK2A1CDK5DYRK1A | |
| SCHEMBL31485528 | 0.83 | CSNK2A1 (0.53) | ABCG2EGFRCHUKCSNK2A1CDK5 | |
| SCHEMBL31485519 | 0.83 | IDO1 (0.45) | EGFRLATS1KDM4CCSNK2A1CDK5 | |
| SCHEMBL31485532 | 0.83 | TNNI3K (0.47) | ABCG2LATS1CSNK2A1 | |
| SCHEMBL31356307 | 0.82 | CHUK (0.45) | ABCG2LATS1CHUKCSNK2A1 | |
| SCHEMBL31485490 | 0.81 | CSNK2A1 (0.51) | ABCG2EGFRCHUKCSNK2A1 | |
| SCHEMBL27199803 | 0.81 | ABCG2 (0.49) | ABCG2KDM1AEGFRLATS1KDM4C | |
| SCHEMBL31356301 | 0.81 | ABCG2 (0.48) | ABCG2KDM1AEGFRLATS1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | claimed |
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | King Faisal University (SA) | 2025-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269826-B1 | 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors | CKS2, CSNK1G1, CSNK2A3 | ABCG2 3122/4885KDM1A 2080/4885EGFR 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.